Speaker Biography

Henrique Faneca

Principal investigator University of Coimbra Portugal

Title: Development of novel nanosystems to mediate combined and multi-target antitumor therapeutic strategies

Henrique Faneca

Henrique Faneca is principal investigator at Centre for Neuroscience and Cell Biology, and invited assistant professor at University of Coimbra. He received his Ph.D. degree in Biochemistry from Coimbra University in 2005. The main focus of his research is the development of lipid- and polymeric-based nanosystems for gene and drug delivery into target cells and the generation of new antitumor strategies, involving different gene therapy approaches either per se or in combination with chemotherapeutic agents. Henrique Faneca is author of more than 45 scientific papers corresponding to over 1500 citations and to an h-index of 19.


Cancer is one of the major causes of death, since conventional available treatments, in most of the cases, do not allow a cure of the disease. Despite the ongoing efforts, current treatment options are associated to multiple limitations, including reduced therapeutic efficacy and high side effects. The lack of effective and well-tolerated cancer treatments highlights the urgent need for the development of new therapeutic approaches, such as those involving the combination of gene therapy and chemotherapy. However, the synchronized application of these two types of strategies requires the development of efficient delivery nanosystems, in order to promote an effective and specific delivery of both therapeutic molecules into tumors, while avoiding their release in healthy tissues.  

In this context, we have recently developed new gene delivery nanosystems, polymer-based ones that have the ability to condense and efficiently deliver genetic material, and lipid-based ones that have the ability to specifically and efficiently deliver genetic material into HCC cells both in vitro and in vivo. Moreover, we have also shown that combination of antitumor gene therapy strategies, such as those including therapeutic genes or anti microRNA oligonucleotides, with low amounts of chemotherapeutic agents could result in a synergistic and significant antitumor effect.

Our present and future work will be focused on the engineering and characterization of novel nanoparticles, for drug and gene delivery, to mediate innovative multi-target antitumor strategies involving the combination of gene therapy and chemotherapy, in order to achieve a much higher antitumor efficacy and less side effects than conventional therapeutic strategies.